KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Net Cash Flow: 2011-2025

Historic Net Cash Flow for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $8.1 million.

  • Supernus Pharmaceuticals' Net Cash Flow rose 139.72% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.1 million, marking a year-over-year increase of 291.35%. This contributed to the annual value of -$5.7 million for FY2024, which is 68.32% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Net Cash Flow is $8.1 million, which was down 71.90% from $28.9 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Net Cash Flow's 5-year high stood at $369.1 million during Q1 2023, with a 5-year trough of -$437.5 million in Q2 2023.
  • Its 3-year average for Net Cash Flow is $5.4 million, with a median of $8.1 million in 2025.
  • Data for Supernus Pharmaceuticals' Net Cash Flow shows a peak YoY increase of 520.75% (in 2023) and a maximum YoY decrease of 858.05% (in 2023) over the last 5 years.
  • Over the past 5 years, Supernus Pharmaceuticals' Net Cash Flow (Quarterly) stood at -$11.8 million in 2021, then tumbled by 55.08% to -$18.4 million in 2022, then fell by 8.49% to -$19.9 million in 2023, then soared by 288.94% to $37.7 million in 2024, then surged by 139.72% to $8.1 million in 2025.
  • Its Net Cash Flow was $8.1 million in Q3 2025, compared to $28.9 million in Q2 2025 and $46.5 million in Q1 2025.